Stock & Company Details
Imunon Inc $IMNN
Price:
46,691,331
4.2M
$7.4M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-0.39
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
IMNN technical indicators
Latest Imunon Inc (IMNN) technical indicators as of 2026-07-21: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
29.28 14.5%
MACD:
-0.07 26.8%
SMA 50:
$2.06 1.0%
SMA 200:
$3.25 0.5%
EMA 20:
$1.90 1.2%
Bollinger Bands:
2.09 / 1.65
Stochastic:
16.51 34.4%
ADX 14:
22.02 0.7%
ATR 14:
0.17 12.8%
CCI 20:
-93.34 11.5%
OBV:
703.80M 0.5%
ROC 12:
-12.57% 114.8%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Finance Bot
Ask your questions
Start by typing a question below.
